Kolexia
Selle Frederic Oncologie médicale
Selle Frederic
Oncologie médicale
Institut Caroline Malvesin
Paris, France
229 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Carcinomes Récidive tumorale locale Tumeurs de la trompe de Fallope Tumeurs embryonnaires et germinales Tumeurs du péritoine Tumeurs de l'endomètre Tumeurs épithéliales épidermoïdes et glandulaires

Collaborateurs

Voir plus
Pautier Patricia
Pautier Patricia
Gustave-Roussy, Villejuif, France
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France
Joly Florence
Joly Florence
Hôpital Côte de Nacre, Caen, France
Floquet Anne
Floquet Anne
Institut Bergonié, Bordeaux, France

Industries

Voir plus
MSD
40 collaboration(s)
Dernière en 2023
GSK
28 collaboration(s)
Dernière en 2023
AstraZeneca
18 collaboration(s)
Dernière en 2022
PUBLICLIN
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   06 mars 2024
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Nature communications   05 mars 2024
SOLO-1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Essai Clinique (AstraZeneca)   28 février 2024
ALEPRO: A Phase II, Open-label, Multicenter Study of Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Essai Clinique (Lilly)   09 février 2024
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Essai Clinique (AstraZeneca)   15 janvier 2024
ATALANTE: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
Essai Clinique (Roche)   02 janvier 2024
ANITA: A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
Essai Clinique (Grupo Español de Investigación en Cáncer de Ovario)   28 décembre 2023
20P Deciphering tumor microenvironment heterogeneity between primary tumor and metastases in high grade serous ovarian cancer (HGSC) to predict response to immunotherapy (IT): Analyses from the NeoPembrOv/GINECO phase II trial
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
GYNET: A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
Essai Clinique (NETRIS Pharma)   24 novembre 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Annals of oncology : official journal of the European Society for Medical Oncology   04 octobre 2023